24
Research for Patient Benefit Overview of the programme in the West Midlands RDS West Midlands Exploring Research Funding Day 9 October 2013 Professor Scott Weich Chair, West Midlands Regional Advisory Committee Bob Scott West Midlands Programme Manager

Research for Patient Benefit Overview of the programme in the West Midlands

  • Upload
    tana

  • View
    53

  • Download
    3

Embed Size (px)

DESCRIPTION

Research for Patient Benefit Overview of the programme in the West Midlands. Professor Scott Weich Chair, West Midlands Regional Advisory Committee Bob Scott West Midlands Programme Manager. RDS West Midlands Exploring Research Funding Day 9 October 2013. Today’s presentation. - PowerPoint PPT Presentation

Citation preview

Page 1: Research for Patient Benefit Overview of the programme in the West Midlands

Research for Patient BenefitOverview of the programme in the West Midlands

RDS West MidlandsExploring Research Funding Day9 October 2013

Professor Scott WeichChair, West Midlands Regional Advisory CommitteeBob ScottWest Midlands Programme Manager

Page 2: Research for Patient Benefit Overview of the programme in the West Midlands

• Background on NIHR and RfPB• RfPB in the West Midlands• Regional statistics update• The application process• Tips for applying and common areas of feedback to

applicants

Today’s presentation

Page 3: Research for Patient Benefit Overview of the programme in the West Midlands

NIHR Remit

• Aims to create a health research system in which the NHS supports outstanding individuals, working in world class facilities, conducting leading edge research focused on the needs of patients and the public

• A range of programmes with a broad range of health priorities

• Funding is based on the quality and relevance of the research to the NHS and personal social services

• Demonstrate the potential to have an impact on the needs of patients and the public within 5 years of its completion

• The NIHR does not fund basic research or work involving animals and/or animal tissue

Page 4: Research for Patient Benefit Overview of the programme in the West Midlands

Infrastructure

Clinical Research Facilities & Centres

Clinical Research Networks

Research

Research Projects & Programmes

Research Governance

Systems

Research Information

Systems

Systems

Patients&

Public

Universities

Investigators &Senior Investigators

Associates

Faculty

Trainees

Research Units & Schools

NHS Trusts

NIHR: a Health Research System

Page 5: Research for Patient Benefit Overview of the programme in the West Midlands

The central role of NIHR research in the innovation pathway

Biomedical Research CentresBiomedical Research Centres

Basic Research

National Institutefor Health Research

This pathway covers the full range of interventions - pharmaceuticals, biologicals, biotechnologies, procedures, therapies and practices - for the full range of health and health care delivery - prevention, detection, diagnosis, prognosis, treatment, care.

Patient Safety Translational Research Centres

Patient Safety Translational Research Centres

Research for Patient BenefitResearch for Patient Benefit

Programme Grants for Applied ResearchProgramme Grants for Applied Research

Health Technology AssessmentHealth Technology Assessment

Invention for InnovationInvention for Innovation

Collaborations for Leadership in Applied Health Research and Care

Collaborations for Leadership in Applied Health Research and Care

Centre for Reviews & Dissemination, Cochrane, TARsCentre for Reviews & Dissemination, Cochrane, TARs

Development Pathway Funding

Public Health ResearchPublic Health Research

Health Services and Delivery ResearchHealth Services and Delivery Research

INVENTION EVALUATION ADOPTION DIFFUSION

Efficacy & Mechanism EvaluationEfficacy & Mechanism Evaluation

NHS Commissioning Board and Clinical Commissioning Groups Commissioning

National Institute for Health & Clinical Excellence Guidance on Health & HealthcareNHS Supply Chain Support for Procurement

NHS Evidence Access to EvidenceInnovationAcademic Health Science Networks

Patient CareProviders of NHS Services

Clinical Research FacilitiesClinical Research Facilities

Experimental Cancer Medicine CentresExperimental Cancer Medicine Centres

Horizon Scanning CentreHorizon Scanning Centre

Centre for Surgical Reconstruction & MicrobiologyCentre for Surgical Reconstruction & Microbiology

Biomedical Research UnitsBiomedical Research Units

MedicalResearch Council

Healthcare Technology Co-operatives Healthcare Technology Co-operatives

Research SchoolsResearch Schools

Page 6: Research for Patient Benefit Overview of the programme in the West Midlands

The RfPB Programme• Response mode funding programme• Budget of up to £25 million per year • Grants may be:

– Costed up to £350,000– Feasibility applications costed up to £250k– Up to 36 months in duration

• Three funding competitions per year• Ten Regional Advisory Committees• > 540 awards made to date totalling nearly £120m

Page 7: Research for Patient Benefit Overview of the programme in the West Midlands

Aims of Programme

• The research projects will use quantitative or qualitative methods to:– Study the way NHS services are provided and used– Evaluate whether interventions are effective and

provide value for money– Examine whether alternative means for providing

healthcare would be more effective– Formally assess innovations and developments in

healthcare– Pilot or assess feasibility of projects requiring major

applications to other funders

Page 8: Research for Patient Benefit Overview of the programme in the West Midlands

Aims of Programme

• Intends to support research which is related to the day-to-day practice of health service staff and is concerned with having an impact on the health of users of the NHS

• Funded research projects are likely to fall into the areas of health service research and public health research, although other areas are not excluded from the programme

• Applications which have emerged from interaction with patients and the public, which relate to patient and service user experience and which have been drawn up in association with a relevant group of service users will be particularly welcome

Page 9: Research for Patient Benefit Overview of the programme in the West Midlands

Research for Patient BenefitSpend across health category(2012-2013)

Generic Health Relevance

9%

Reproductive 4.5%

Mental Health 23%

Oral and Gastrointestinal

4.5%

Neurological 7.5%

Stroke 8%

Cancer 10%

Musculoskeletal 4%

Metabolic and Endocrine5%

Renal and Urogenital 5%

Cardiovascular6%

Injuries and Accidents 3%

Page 10: Research for Patient Benefit Overview of the programme in the West Midlands

• 60 projects funded by RfPB of 398 applications received• 71% of applications successful at preliminary

scrutiny/scoping stage (69% national average)• 21% of peer reviewed applications successful for

funding (23% national average)• Regional Panel Chair – Professor Scott Weich (from Jan 2013) • Programme Manager – Bob Scott

RfPB in the West Midlands

Page 11: Research for Patient Benefit Overview of the programme in the West Midlands

Preliminary Scrutiny

Page 12: Research for Patient Benefit Overview of the programme in the West Midlands

Recommended for Funding

Page 13: Research for Patient Benefit Overview of the programme in the West Midlands

Overall Success Rate

Page 14: Research for Patient Benefit Overview of the programme in the West Midlands

Application Process

• Once registered on the Research Management System portal, applicants have access to all CCF programmes

• Application form supports full formatting• Edit options allow work to be saved and returned to at a

later time• Invited co-applicants can also edit the form• All co-applicants must confirm their involvement

and approve the application prior to submission• Only the lead applicant can submit the application • Declarations and signatures are due within a week and

must be signed by contracting NHS body• All applications are validated by CCF

Page 15: Research for Patient Benefit Overview of the programme in the West Midlands

Preliminary Scrutiny

• Reduction in the number of submitted applications over recent competitions

• Appreciation of the effort and resource involved in preparing an application

• Alternative process to be piloted for Competition 22• A ‘light-touch’ preliminary scrutiny process to be carried

out on the basis of programme scope• Fewer applications rejected on the basis of

methodology• Increased percentage of applications assessed by peer

review and Committee

Page 16: Research for Patient Benefit Overview of the programme in the West Midlands

Peer Review

• A key part of the assessment process and integral to Committee recommendations

• At least three expert reviews and one public review per application

• Includes opinion on: – Relevance of the research– Quality of the design and work plan– Strength of the research team– Potential impact of the study – Value for money– Involvement of patients and the public

• Anonymised and redacted reviews provided to applicants with Committee feedback at outcome

Page 17: Research for Patient Benefit Overview of the programme in the West Midlands

Committee Assessment

• West Midlands Committee comprises 16 academic members and 3 public members

• Members of the RDS with methodological expertise sit on committees in neighbouring regions

• Committee meetings held three times a year, with a maximum of 15 applications at each meeting

• Conflicts are minimised by the re-allocation of applications to other regions if required.

• All applications are presented to the Committee by two expert lead assessors and one public member assessor

• Feedback provided to all applicants

Page 18: Research for Patient Benefit Overview of the programme in the West Midlands

• Methodology lacking or design questions• Overall lack of clarity and focus of the application• Inappropriate outcome measures• Expertise lacking in the research team• Insufficient quality of the patient and public involvement• Justification or detail of the intervention lacking• Insufficient detail in background information• Inappropriate statistics or health economics analysis• Concerns about recruitment, sampling or feasibility• Project impact, timescales, generalisability or

dissemination

Common areas for feedback

Page 19: Research for Patient Benefit Overview of the programme in the West Midlands

Feedback to applicants

Page 20: Research for Patient Benefit Overview of the programme in the West Midlands

What makes a successful RfPB application?• Important question and clear aims• Do your homework & don’t overlook key references• Strong team with appropriate expertise & balance• Convincing research design inc sample size• Explaining how the evidence will benefit patients • Evidence of meaningful patient and public involvement• Justify outcomes & ensure these match aims• Seeking & listening to advice from the RDS• Value for money• If feasibility study, will the full trial be fundable?

Page 21: Research for Patient Benefit Overview of the programme in the West Midlands

Other things to keep in mind

• All project costs are scrutinised by CCF – particular attention should be paid to NHS service support, treatment and excess treatment costs

• Patient and public involvement must be adequately thought through and costed

• Plain English Summary should be reviewed by a public contributor

• Relevance to patients and NHS is important• Read the guidance and website resources• All deadlines are at 1pm exactly so don’t leave it to the

last minute

Page 22: Research for Patient Benefit Overview of the programme in the West Midlands

Research Costs are the costs of the R&D itself; data collection, analysis and other activities needed to answer the research questions.• Research Costs will be met by the research funder (i.e. RfPB)

NHS Support Costs include the additional patient-related care costs associated with the research, which would end once the R&D activity in question had stopped, even if the patient care service involved continued to be provided.• NHS Support Costs will be met by NHS R&D Support Funding (i.e. Networks) Treatment Costs are the patient care costs which would continue to be incurred if the patient care service in question continued to be provided after the R&D activity had stopped. Excess Treatment cost is the difference between the total Treatment Costs and the costs of the standard treatment currently provided.• NHS Treatment Costs will be met through commissioning arrangements for patient care (i.e. NHS/contracting organisation)

Guidance: Attributing the costs of health and social care Research & Development (AcoRD) – updated 4 May 2012

The costs of R&D in the NHS

Page 23: Research for Patient Benefit Overview of the programme in the West Midlands

Tips for applicants

• Read the Guidance for applicants and FAQs (RfPB website)

• Ensure originality – thorough literature review

• Assemble the right team for the task

• Write clearly and for a broad audience

• Describe clearly how the research will benefit patients

• Don’t be over-ambitious

– Can you recruit in the time available?

– Are recruitment estimates realistic?

• Don’t forget to allow time for gaining ethical approval

• Have you left enough analysis and write-up time?

Page 24: Research for Patient Benefit Overview of the programme in the West Midlands

Thank you

RfPB Helpline : 020 8843 8057

www.rfpb.nihr.ac.uk